Deep Molecular Characterization of Milder Spinal Muscular Atrophy Patients Carrying the c.859G>C Variant in SMN2


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
27 07 2022
Historique:
received: 22 06 2022
revised: 20 07 2022
accepted: 22 07 2022
entrez: 12 8 2022
pubmed: 13 8 2022
medline: 16 8 2022
Statut: epublish

Résumé

Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by biallelic loss or pathogenic variants in the SMN1 gene. Copy number and modifier intragenic variants in SMN2, an almost identical paralog gene of SMN1, are known to influence the amount of complete SMN proteins. Therefore, SMN2 is considered the main phenotypic modifier of SMA, although genotype−phenotype correlation is not absolute. We present eleven unrelated SMA patients with milder phenotypes carrying the c.859G>C-positive modifier variant in SMN2. All were studied by a specific NGS method to allow a deep characterization of the entire SMN region. Analysis of two homozygous cases for the variant allowed us to identify a specific haplotype, Smn2-859C.1, in association with c.859G>C. Two other cases with the c.859G>C variant in their two SMN2 copies showed a second haplotype, Smn2-859C.2, in cis with Smn2-859C.1, assembling a more complex allele. We also identified a previously unreported variant in intron 2a exclusively linked to the Smn2-859C.1 haplotype (c.154-1141G>A), further suggesting that this region has been ancestrally conserved. The deep molecular characterization of SMN2 in our cohort highlights the importance of testing c.859G>C, as well as accurately assessing the SMN2 region in SMA patients to gain insight into the complex genotype−phenotype correlations and improve prognostic outcomes.

Identifiants

pubmed: 35955418
pii: ijms23158289
doi: 10.3390/ijms23158289
pmc: PMC9368089
pii:
doi:

Substances chimiques

SMN2 protein, human 0
Survival of Motor Neuron 1 Protein 0
Survival of Motor Neuron 2 Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Biogen
ID : ESP-SMG-17-11256
Organisme : Instituto de Salud Carlos III
ID : FIS PI18/000687

Références

Plant Methods. 2012 Aug 24;8(1):34
pubmed: 22920499
Hum Genet. 2019 Mar;138(3):241-256
pubmed: 30788592
Bioinformatics. 2011 Nov 15;27(22):3216-7
pubmed: 21965822
Front Neurol. 2021 May 06;12:663911
pubmed: 34025568
J Child Neurol. 2007 Aug;22(8):1027-49
pubmed: 17761659
Hum Mol Genet. 1999 Jul;8(7):1177-83
pubmed: 10369862
Am J Pathol. 2007 Oct;171(4):1269-80
pubmed: 17717146
Arch Neurol. 1995 May;52(5):518-23
pubmed: 7733848
J Neuromuscul Dis. 2020;7(1):1-13
pubmed: 31707373
Neurol Genet. 2020 Nov 18;6(6):e530
pubmed: 33324756
J Med Genet. 2010 Sep;47(9):640-2
pubmed: 20577007
Hum Genet. 2001 Mar;108(3):255-66
pubmed: 11354640
Hum Mol Genet. 2017 Jul 15;26(14):2768-2780
pubmed: 28460014
Sci Rep. 2015 Jun 26;5:11696
pubmed: 26114395
J Neuropathol Exp Neurol. 2005 Mar;64(3):215-23
pubmed: 15804053
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Eur J Pediatr. 2022 Jul;181(7):2821-2829
pubmed: 35522315
Cell. 1995 Jan 13;80(1):155-65
pubmed: 7813012
Neuromuscul Disord. 2017 Oct;27(10):883-889
pubmed: 28757001
Eur J Neurol. 2021 Feb;28(2):609-619
pubmed: 33090613
J Med Genet. 2003 Apr;40(4):e39
pubmed: 12676912
Cell. 2019 Jan 24;176(3):535-548.e24
pubmed: 30661751
Curr Opin Genet Dev. 2013 Jun;23(3):330-8
pubmed: 23602330
Hum Genet. 2009 Feb;125(1):29-39
pubmed: 19050931
Hum Mutat. 2010 Jan;31(1):E1110-25
pubmed: 19953646
Neuromuscul Disord. 1997 May;7(3):202-7
pubmed: 9185186
Genome Res. 2011 Aug;21(8):1360-74
pubmed: 21659425
Brain Commun. 2020 Jun 08;2(2):fcaa075
pubmed: 32954327
Genet Med. 2011 Jul;13(7):686-94
pubmed: 21673580
Genet Test Mol Biomarkers. 2011 Sep;15(9):587-94
pubmed: 21548796
Eur J Hum Genet. 2012 Jan;20(1):27-32
pubmed: 21811307
Int J Mol Sci. 2021 Aug 21;22(16):
pubmed: 34445733
Am J Hum Genet. 2009 Sep;85(3):408-13
pubmed: 19716110
Hum Mutat. 2021 Jun;42(6):787-795
pubmed: 33739559
Neuromuscul Disord. 2018 Mar;28(3):208-215
pubmed: 29433793

Auteurs

Laura Blasco-Pérez (L)

Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Mar Costa-Roger (M)

Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Jordi Leno-Colorado (J)

Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Sara Bernal (S)

Genetics Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.

Laura Alias (L)

Genetics Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.

Marta Codina-Solà (M)

Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Desirée Martínez-Cruz (D)

Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Claudia Castiglioni (C)

Departamento de Neurología Pediátrica, Clínica Las Condes, 7591047 Santiago de Chile, Chile.

Enrico Bertini (E)

Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesu, IRCCS, 00165 Rome, Italy.

Lorena Travaglini (L)

Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesu, IRCCS, 00165 Rome, Italy.

José M Millán (JM)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Unidad de Genética, Hospital La Fe and IIS La Fe, 46026 Valencia, Spain.

Elena Aller (E)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Unidad de Genética, Hospital La Fe and IIS La Fe, 46026 Valencia, Spain.

Javier Sotoca (J)

Neuromuscular Diseases Unit, Neurology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.

Raúl Juntas (R)

Neuromuscular Diseases Unit, Neurology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.

Christina Engel Hoei-Hansen (CE)

Department of Paediatrics, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, 1165 Copenhagen, Denmark.

Antonio Moreno-Escribano (A)

Neurology Service and Medical Genetics Section, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Universidad de Murcia, 30120,Murcia, Spain.

Encarna Guillén-Navarro (E)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Neurology Service and Medical Genetics Section, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Universidad de Murcia, 30120,Murcia, Spain.

Laura Costa-Comellas (L)

Pediatric Neurology Section, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Francina Munell (F)

Pediatric Neurology Section, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Susana Boronat (S)

Pediatrics Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.

Ricardo Rojas-García (R)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
MND Clinic, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain.

Mónica Povedano (M)

Unidad Funcional de Enfermedad de Motoneurona, Servicio de Neurología, Hospital Universitario de Bellvitge, 08907 Barcelona, Spain.

Ivon Cuscó (I)

Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.

Eduardo F Tizzano (EF)

Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH